INVA vs. VIR, OCUL, KNSA, CVAC, PHAT, CDMO, TBPH, INO, SUPN, and AXSM
Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Vir Biotechnology (VIR), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), CureVac (CVAC), Phathom Pharmaceuticals (PHAT), Avid Bioservices (CDMO), Theravance Biopharma (TBPH), Inovio Pharmaceuticals (INO), Supernus Pharmaceuticals (SUPN), and Axsome Therapeutics (AXSM). These companies are all part of the "medical" sector.
Innoviva (NASDAQ:INVA) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Innoviva received 257 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 57.28% of users gave Innoviva an outperform vote while only 47.50% of users gave Vir Biotechnology an outperform vote.
Innoviva has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 57.89% compared to Vir Biotechnology's net margin of -677.69%. Innoviva's return on equity of 30.37% beat Vir Biotechnology's return on equity.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 1.4% of Innoviva shares are held by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Innoviva has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
Vir Biotechnology has a consensus price target of $34.63, suggesting a potential upside of 233.25%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Innoviva.
In the previous week, Vir Biotechnology had 20 more articles in the media than Innoviva. MarketBeat recorded 21 mentions for Vir Biotechnology and 1 mentions for Innoviva. Innoviva's average media sentiment score of 1.76 beat Vir Biotechnology's score of 0.63 indicating that Innoviva is being referred to more favorably in the media.
Summary
Innoviva beats Vir Biotechnology on 12 of the 17 factors compared between the two stocks.
Get Innoviva News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innoviva Competitors List
Related Companies and Tools
